41 results about "Hepatic ischemia" patented technology

The invention provides a liver perfusate, which is prepared by 5,500 to 6,500 mg / L of sodium chloride, 250 to 350 mg / L of potassium chloride, 150 to 250 mg / L of calcium chloride, 3,000 to 3,200 mg / L of sodium lactate, 4 to 6 mmol / L of 1, 6-diphosphofructose, 5 to 15 mg / L of dexamethasone, 2.5 to 3.5 mmol / L of reduced glutathione, and 4 to 6mg / L of verapamil. The product has a simple formula, convenient configuration, low cost and proper potassium concentration, can be safely used for the preservation of isolated organs, more importantly can be applied to the perfusion protection of vivo organs, and can effectively prevent the injury of hepatic ischemia reperfusion. The invention also provides two preparation methods for the liver perfusate.

The invention discloses an application of Caspase recruitment domain protein 6 (Card6) in hepatic ischemia reperfusion injury and belongs to the field of functions and applications of genes. According to the application, hepatic-cell specific Card6 gene knockout mice and Card6 transgenic mice serve as experimental subjects, functions of a Card6 gene are researched through a hepatic ischemia reperfusion injury model, and the condition that Card6 plays a role in improving the hepatic ischemia reperfusion injury is discovered, so that the Card6 has the applications as follows: an application of the Card6 in screening of drugs for preventing, relieving and / or treating the hepatic ischemia reperfusion injury as a drug target, wherein the screening of the drugs for preventing, relieving and / or treating the hepatic ischemia reperfusion injury means screening the drugs capable of promoting Card6 expression; an application of the Card6 in preparation of drugs for preventing, relieving and / or treating the hepatic ischemia reperfusion injury.

The invention discloses the application of a TRAF1 inhibitor in liver ischemic diseases, and belongs to the field of biomedicine. In the present invention, TRAF1 gene knockout mice and hepatocyte-specific TRAF1 transgenic mice are used as experimental objects, and the hepatic ischemia-reperfusion injury model is used. The results show that compared with wild-type C57 mice, TRAF1 gene knockout mice have obvious liver necrosis Inhibited, liver function also significantly improved, while hepatic cell-specific TRAF1 transgenic mice had significantly increased liver necrosis and significantly worsened liver function. Therefore, TRAF1 gene has the effect of deteriorating liver function, especially TRAF1 gene can aggravate hepatic ischemic disease. According to the above functions of TRAF1, TRAF1 is provided as a drug target for the treatment of liver ischemic diseases and applied in the development of drugs for liver ischemic diseases.

The invention discloses application of dual-specificity phosphatase 14(Dusp14) to hepatic ischemia reperfusion injury, and belongs to the field of gene functions and application. A mouse with a hepatocyte-specific Dusp14 gene deleted and a Dusp14 transgenic mouse serve as experiment objects, the functions of the Dusp14 gene are studied through a hepatic ischemia reperfusion injury model, and it is found that the Dusp14 has an effect of improving the hepatic ischemia reperfusion injury. Thus, the Dusp14 has the following application: the application of the Dusp14 as a medicine target to screening medicines for preventing, relieving and / or treating the hepatic ischemia reperfusion injury and the application of the Dusp14 to preparing the medicines for preventing, relieving and / or treating the hepatic ischemia reperfusion injury, wherein screening the medicines for preventing, relieving and / or treating the hepatic ischemia reperfusion injury refers to screening the medicines capable of promoting Dusp14 expression.